By ParadigMS Foundation
As a warm-up for the Sixth MENACTRIMS Congress, ParadigMS Foundation is organising an enriching Pre-MENACTRIMS Symposium on Thursday December 9.
The Sixth Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS) Congress will take place December 10 & 11, 2021 at the Intercontinental Hotel, Dubai, United Arab Emirates.
This symposium and the Congress are taking place in a hybrid format, offering many exciting possibilities to grow your network, transfer knowledge and explore the latest industry developments.
Pre-MENACTRIMS Symposium
Date & Time:
Thursday, December 9, 2021 at 18:00 (+4 GMT Dubai Time)
Location:
Online and Al Baraha 1, Intercontinental Hotel, Dubai
17:30-18:00 Registration
18:00-18:05 Welcome and Introduction
18:05-19:30 Lectures (Chairs: B. Yamout (AE) & C. Oreja-Guevara (ES))
18:05-18:25 Pregnancy and Lactation in Patients with MS B. Yamout (AE)
18:25-18:30 Live Q&A
18:30-18:50 Human response to COVID-vaccination in MS C. Oreja-Guevara (ES)
18:50-18:55 Live Q&A
18:55-19:15 How to Mitigate Risks in MS M. Pugliatti (IT)
19:15-19:30 Hot Topics Panel Discussion
19:30-20:00 Coffee and Networking
With the support of :
Merck, Global Medical Education & Academic Organization Relations
Access the Merck knowledge forum at academe-ms.com
Abstracts
Pregnancy and Lactation in Patients with MS (By Prof Bassem Yamout)
This session will present the most recent findings and updates for the treatment of pregnant or lactating MS patients. This includes family planning; the effect of pregnancy on the disease course, including relapses; post-partum disease activity; treatment during pregnancy and breastfeeding and the compatibility of disease modifying therapies and breastfeeding. The conclusions will illustrate how to support patients making informed decisions on the basis of the presented information.
Human response to COVID-vaccination in MS (By Prof Celia Oreja-Guevara)
Most multiple sclerosis (MS) patients infected with COVI-19 had a mild-moderate infection, with no more relapses or more severe disease course than MS-free patients. This session will shed light on the response to vaccination of MS patients, including the influence of the chosen MS treatment on vaccine response. Join to hear more about the production of antibodies in vaccinated MS patients and the influence of the MS treatment on antibodies production.
How to Mitigate Risks in MS (By Prof Maura Pugliatti)
No two MS patients are the same, and yet only a limited number of disease-modifying therapies are available for MS neurologists to treat their patients. This session will guide you in how to manage and mitigate risks associated with treating MS patients. You will take away a set of key messages stemming both from Professor Pugliatti’s own experience and literature reports, underlying risk mitigation in MS treatment.
More information about the MENACTRIMS Congress
The congress aim is to provide a forum of excellence in MS education and research. Building on the collective efforts of the scientific committee, the meeting will deliver state-of-the-art presentations on MS by renowned international and regional keynote speakers. The content of the meeting includes up to date information on the latest treatments, clinical research, therapeutic strategies, pathology, imaging, epidemiology, diagnosis, biomarkers, neuromyelitis optica, and much more.
More info: 2021.menactrims.com
